Healthcare startups are running into the same problems

Interoperability is the big problem that seems to smack all new entries in the healthcare innovations area. While many technology companies see a huge opportunity in the $3.5 trillion industry, the inability to share data seamlessly between providers for clinical and billing information is preventing many from scaling up, according to a report by CNBC.

In addition to stopping technology companies from growing in the healthcare space, interoperability may also be contributing to the ever-higher prices in the market, according to Paul Markovich, CEO of Blue Shield of California, who spoke with CNBC.

According to Markovich, even the efforts of big tech businesses like Apple, with its Health Records initiative, could be a 10-year project to get data from every hospital, clinic and health plan without a new, concerted effort to improve health data sharing.

Fortunately, signals from HHS on efforts to improve patient access to health records are promising, he said. And Blue Shield of California is also jumping into the issue through new pilot programs and technology partners.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.